Welcome to our dedicated page for Karyopharm Therapeutics news (Ticker: KPTI), a resource for investors and traders seeking the latest updates and insights on Karyopharm Therapeutics stock.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company focused on novel cancer therapies that target nuclear export dysregulation. Its lead product, XPOVIO (selinexor), is a first-in-class, oral exportin 1 (XPO1) inhibitor approved in the U.S. in multiple oncology indications and in various indications across more than 50 ex-U.S. territories and countries, according to company statements.
This news page aggregates company-issued updates and market disclosures related to Karyopharm. Readers can follow announcements on XPOVIO commercial performance, such as reported U.S. net product revenue and trends in license and royalty revenue from international partners, as described in the company’s earnings releases. The feed also covers progress in Karyopharm’s clinical pipeline, including multiple myeloma, endometrial cancer, myelofibrosis and diffuse large B-cell lymphoma (DLBCL).
Recent news has highlighted key milestones in late-stage development, including completion of enrollment in the Phase 3 SENTRY trial (XPORT-MF-034) in myelofibrosis and ongoing enrollment in the global Phase 3 XPORT-EC-042 trial in TP53 wild-type advanced or recurrent endometrial cancer. Company releases also describe Phase 2 data in heavily pretreated myelofibrosis patients and the design of additional studies such as SENTRY-2 and XPORT-MM-031 in multiple myeloma.
In addition to clinical and commercial updates, Karyopharm’s news includes financial results, preliminary revenue disclosures, strategic financing transactions involving term loans and convertible notes, and inducement equity awards granted under its inducement stock incentive plan. Investors and observers can use this page to review the company’s own descriptions of its operational progress, financing activities and anticipated clinical catalysts as reported in press releases and referenced in SEC filings.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced the grant of stock options for 124,500 shares to 15 newly-hired employees, effective January 31, 2022. The exercise price is set at $8.90 per share, reflecting the stock's closing price on the grant date. Options will vest over four years, with 25% vesting after one year and the remainder monthly. The options are also subject to immediate exercise if the employee's role is terminated without cause within a year following a 'change in control.' This move aligns with Nasdaq rules for inducements to new hires.
Karyopharm Therapeutics (Nasdaq: KPTI) announced the FDA granted orphan drug designation for eltanexor, a novel oral SINE compound, aimed at treating myelodysplastic syndromes (MDS). This designation supports the development of therapies for conditions affecting fewer than 200,000 patients annually, offering incentives such as potential market exclusivity. Eltanexor has shown a 53% overall response rate in clinical trials for HMA-refractory MDS, significantly improving survival rates compared to standard treatments. Karyopharm remains focused on advancing its clinical trials to provide new options for patients.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced that President and CEO Richard Paulson will present virtually at the B. Riley Securities Oncology Investor Conference on January 28, 2022, at 9:30 a.m. ET. Investors can access a live webcast of the presentation under the 'Events & Presentations' section of Karyopharm's website. The company specializes in innovative cancer therapies and is known for its lead compound, XPOVIO® (selinexor), which has received multiple regulatory approvals. For more details, visit www.karyopharm.com.
Karyopharm Therapeutics (Nasdaq: KPTI) has announced the promotion of Sohanya Cheng to Chief Commercial Officer, effective immediately. Cheng's role includes directing the company's commercial strategy, particularly the ongoing commercialization of XPOVIO® (selinexor). With 18 years of experience in oncology and significant contributions to Karyopharm's revenue increase in 2021, her leadership is anticipated to strengthen the company’s market position. Karyopharm continues to focus on expanding its oncology portfolio and preparing for forthcoming clinical trial results.
Karyopharm Therapeutics (Nasdaq: KPTI) reported preliminary unaudited net product revenues of approximately $29.7 million for Q4 2021 and $98.3 million for the full year. The company is focused on advancing its pipeline with upcoming results from the Phase 3 SIENDO study for selinexor in advanced endometrial cancer expected this quarter. Karyopharm aims to increase sales and adoption of XPOVIO in multiple myeloma and has partnered with Menarini for further commercialization. Notable 2021 achievements include gaining conditional marketing authorization in Europe and the UK for NEXPOVIO.
Karyopharm Therapeutics (Nasdaq: KPTI), a leader in cancer therapies, announced that CEO Richard Paulson will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11 at 3:45 p.m. ET. There will be a Q&A session at 4:05 p.m. ET. The presentation will be held virtually, and a live webcast, along with presentation slides, will be available on the company’s investor website for 30 days post-event. Karyopharm specializes in innovative treatments targeting nuclear export for cancer and other diseases.
Karyopharm Therapeutics (Nasdaq: KPTI) announced the granting of stock options for 5,600 shares to two new employees, effective December 31, 2021. The options, priced at $6.43 per share, are part of an inducement package compliant with Nasdaq Listing Rule 5635(c)(4). Each option vests over four years, with a portion vesting upon the one-year employment anniversary. Immediate exercise is possible upon termination for good reason or without cause within a year of a change in control. Karyopharm focuses on developing innovative cancer therapies, notably XPOVIO®, for various malignancies.
Karyopharm Therapeutics (KPTI) has entered an exclusive licensing agreement with Menarini Group to commercialize NEXPOVIO (selinexor) across Europe and other global territories. In exchange, Karyopharm will receive a $75 million upfront payment and be eligible for up to $202.5 million in future milestones, plus royalties on net sales. NEXPOVIO is conditionally authorized in the EU for treating multiple myeloma patients who have undergone at least four prior therapies. The partnership aims to enhance patient access to this innovative cancer therapy.
Karyopharm Therapeutics (Nasdaq: KPTI) has signed an exclusive licensing agreement with Menarini Group for the commercialization of NEXPOVIO (selinexor) in Europe and other regions. Karyopharm will receive an upfront payment of $75 million and potential milestones of up to $202.5 million, plus royalties on sales. NEXPOVIO, already authorized in the EU for treating multiple myeloma, may expand to additional oncology indications. This partnership aims to enhance patient access to innovative cancer treatments across key global markets.
Karyopharm Therapeutics (KPTI) announced that its partner, Antengene Corporation, received conditional approval from China's NMPA for XPOVIO (selinexor) in combination with dexamethasone for relapsed or refractory multiple myeloma patients. This approval follows positive results from the Phase 2 STORM trial and Antengene's Phase 2 MARCH trial in China. The Phase 3 BENCH trial will serve as a confirmatory trial. CEO Richard Paulson highlighted the significance of this approval in providing new treatment options for patients. Karyopharm remains focused on expanding XPOVIO's availability globally.